Supernus Pharmaceuticals
Stock Forecast, Prediction & Price Target
Supernus Pharmaceuticals Financial Estimates
Supernus Pharmaceuticals Revenue Estimates
Supernus Pharmaceuticals EBITDA Estimates
Supernus Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $579.77M N/A | $667.23M 15.08% | $607.52M -8.94% | Avg: $624.60M Low: $593.32M High: $662.93M avg. 2.81% | Avg: $693.45M Low: $669.11M High: $720.74M avg. 11.02% | Avg: $779.28M Low: $751.93M High: $809.95M avg. 12.37% | Avg: $835.70M Low: $806.37M High: $868.59M avg. 7.23% |
Net Income
% change YoY
| $53.42M N/A | $60.71M 13.63% | $1.31M -97.83% | Avg: $-41.89M Low: $-43.17M High: $-39.20M avg. -3283.51% | Avg: $44.24M Low: $40.79M High: $44.92M avg. 205.59% | Avg: $221.47M Low: $211.36M High: $232.80M avg. 400.60% | Avg: $266.43M Low: $254.27M High: $280.06M avg. 20.30% |
EBITDA
% change YoY
| $120.05M N/A | $149.93M 24.88% | $90.04M -39.94% | Avg: $178.68M Low: $169.73M High: $189.65M avg. 98.44% | Avg: $198.38M Low: $191.42M High: $206.19M avg. 11.02% | Avg: $222.93M Low: $215.11M High: $231.71M avg. 12.37% | Avg: $239.07M Low: $230.68M High: $248.48M avg. 7.23% |
EPS
% change YoY
| $1.01 N/A | $1.13 11.88% | $0.02 -97.86% | Avg: -$0.74 Low: -$0.78 High: -$0.71 avg. -3170.53% | Avg: $0.77 Low: $0.73 High: $0.81 avg. 204.05% | Avg: $3.99 Low: $3.81 High: $4.19 avg. 418.18% | Avg: $4.8 Low: $4.58 High: $5.05 avg. 20.30% |
Operating Expenses
% change YoY
| $425.21M N/A | $534.40M 25.67% | $529.01M -1.00% | Avg: $304.01M Low: $288.78M High: $322.67M avg. -42.53% | Avg: $337.52M Low: $325.67M High: $350.80M avg. 11.02% | Avg: $379.30M Low: $365.98M High: $394.22M avg. 12.37% | Avg: $406.76M Low: $392.48M High: $422.77M avg. 7.23% |
FAQ
What is Supernus Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -664.25% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -43.17M, average is -41.89M and high is -39.20M.
What is Supernus Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.36% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $593.32M, average is $624.60M and high is $662.93M.
What is Supernus Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -632.00% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.78, average is -$0.74 and high is $-0.70.
What is the best performing analyst?
In the last twelve months analysts have been covering Supernus Pharmaceuticals stock. The most successful analyst is David Amsellem.